



## What you should know about **ibuprofen and COVID-19**

**GET THE FACTS**

### **To Our Medical Professional Community,**

We at GSK Consumer Healthcare want to thank you for your continued commitment to keeping Canada safe and healthy. As healthcare professionals, you are essential to the fight against COVID-19, and we are proud to be your partner. Together we can ensure that Canadians have the information they need to do more, feel better and live longer.

An unfortunate consequence of this unprecedented health situation is the spread of speculation and misinformation. Specifically, without supportive clinical evidence, the use of ibuprofen in patients with COVID-19 has been called into question.

At GSK Consumer Healthcare, we understand your need to have the correct information to feel confident in your treatment decisions and to address your patients' questions and concerns.

We would like to address this speculation directly:

**There is no scientific evidence that directly links the use of ibuprofen or other anti-inflammatories with worsened outcomes in patients suffering from COVID-19 infection.**

This is an emerging and rapidly evolving situation, and because consumer safety is our foremost priority, we are closely monitoring independent statements from respected public health authorities and medical experts.

Please visit the **GSK Health Partner Portal** for the latest information, including position statements from Health Canada, WHO, NIH, Canadian Pharmacists Association and Canadian Paediatric Society.

To provide you with the tools you need to help counsel your patients, the portal includes frequently asked questions about the use of ibuprofen in patients with COVID-19.

**GO TO THE PORTAL**

Go to **[bit.ly/2XeV4L9](https://bit.ly/2XeV4L9)** for more information.

We hope the information provided in the **GSK Health Partner Portal** will help you to feel confident about using ibuprofen appropriately as a fever and pain reducer to provide comfort and care for your patients with COVID-19.

We remain committed to providing balanced information about our medicines, maintaining transparency about our work, operating with integrity, and always putting the interests of patients first.

Thank you and stay safe.

**GlaxoSmithKline Consumer Healthcare Canada**

Please consult the Product Monograph available upon request (1-855-367-7349) or on the Health Canada website for information to assist in benefit-risk assessment. Always direct the patient to read the label. Terms of Market Authorization is also available upon request through 1-855-367-7349.